Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery

Launched by INSTITUT DE RECERCA BIOMÈDICA DE LLEIDA · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how genetics and other factors can help predict how well people will lose weight after bariatric surgery, which is a type of surgery to help with severe obesity. The researchers want to understand why some patients lose weight successfully while others do not, as about 30% of people do not achieve satisfactory results from this surgery. They will gather information from nearly 7,000 men and women who have had either sleeve gastrectomy or gastric bypass surgery and analyze various genetic and health factors to find out what influences weight loss and maintenance over 3 years.

To participate in this trial, you must be between 18 and 65 years old and have a body mass index (BMI) of 35 or higher with related health issues, or a BMI over 40. You should not have had any previous gastrointestinal surgeries or be currently using certain weight loss medications. If you decide to join, you can expect to provide some detailed health information and undergo regular follow-ups to track your weight loss progress and any changes in your health. This trial aims to improve treatment for obesity by tailoring approaches to individual needs, which could lead to better outcomes in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and women between the ages of 18 and 65 at the time of surgery
• • SG or RYBP as bariatric procedure.
• • With a BMI≥35.0 kg/m2 with one or more comorbidities or a BMI\>40.0 kg/m2 at the time of surgery.
• • Provision of an informed consent form signed and personally dated by the patient.
• • With available baseline data (anthropometric, analytical, surgical procedure, pharmacological therapies, and obesity-related comorbidities).
• Exclusion Criteria:
• • Any previous gastrointestinal surgery
• • Treatment with any approved antiobesity drug in Spain (orlistat, liraglutide 3.0 mg and/or naltrexone/bupropion extended release) or systemic glucocorticoids for more than 4 consecutive weeks during the 3 years following BS
• • End stage kidney disease (eGFR \<15 ml/min/1.73m2) or liver cirrhosis at baseline
• • Patients who developed any major medical conditions that limits the practice of a healthy life within normal limits (advanced cardiovascular disease or heart failure, stroke with neurological sequelae, chronic pulmonary obstructive disease with dyspnea at minimal exertion, severe joint pathology, end stage renal failure, or active cancer)
• • Known type 1 diabetes or LADA diabetes
• • Women who become pregnant during the follow-up period
• • Current drug or alcohol abuse
• • Uncontrolled psychiatric illness or eating disorders developed during the follow-up period.